<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888640</url>
  </required_header>
  <id_info>
    <org_study_id>201110717</org_study_id>
    <nct_id>NCT01888640</nct_id>
  </id_info>
  <brief_title>Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)</brief_title>
  <acronym>FAST</acronym>
  <official_title>Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathleen Sluka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain associated with fibromyalgia interferes with daily function, work, and social activities
      resulting in a decreased quality of life. People with fibromyalgia also have a significant
      amount of fatigue and a fear of movement. People with fibromyalgia show enhanced excitability
      of pain neurons in the central nervous system and reduced pain inhibition. Therefore, one of
      the main treatments for patients with fibromyalgia must focus on pain relief to allow the
      person to function more independently both at home and at work. Transcutaneous electrical
      nerve stimulation is used by health professionals to deliver electrical stimulation through
      the skin for pain control. Basic science studies, from the PI's laboratory show that TENS
      activates descending pain inhibitory pathways to inhibit excitability of pain neurons. Thus
      the ideal patient population for the treatment of TENS would be one in which there is
      enhanced central excitability and reduced inhibition; fibromyalgia is such a condition.

      Hypothesis: The investigators hypothesize that application of Transcutaneous Electrical Nerve
      Stimulation (TENS) to patients with fibromyalgia will reduce resting and movement-related
      pain and reduce central excitability by restoring diffuse noxious inhibitory controls (DNIC),
      and that this decrease in pain and/or central excitability will reduce fatigue and fear of
      movement, thereby improving function and quality of life
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II randomized, double-blind, placebo controlled multi-center clinical trial
      involving a device, Transcutaneous Electrical Nerve Stimulation (TENS). TENS is a
      non-pharmacological agent which delivers electrical stimulation by a battery operated device
      via electrodes placed on the skin. TENS is considered to be a safe, inexpensive and
      non-invasive modality used to treat a variety of acute and chronic pain conditions. The
      initial phase of the study will randomly allocate subjects to receive active TENS, placebo
      TENS or standard care (No TENS). After participating in the 1 month random assignment, all
      subjects will receive active TENS for 1 month. The subjects will make 4 visits to the clinic
      approximately 2 to 3 1/2 hours each visit. Visits will entail questionnaires, functional
      tasks, accelerometry, TENS, pain and fatigue assessments.

      Study Aims:

      Aim #1: The primary aim of the study is to test the effectiveness of repeated TENS use on
      movement-related pain in people with fibromyalgia with random assignment to three treatments:
      standard care, placebo TENS and active Aim #2: A secondary aim will test if pain reduction by
      TENs results in a concomitant decrease in fatigue and fear of movement, and an increase in
      function and quality of life. Outcome measures will include physical function by directly
      assessing daily activity with an accelerometer, as well as performing specific functional
      tasks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2013</start_date>
  <completion_date type="Actual">April 2, 2018</completion_date>
  <primary_completion_date type="Actual">April 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS</time_frame>
    <description>Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resting Pain (0-10 Low to High Scale)</measure>
    <time_frame>Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)</time_frame>
    <description>Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting Fatigue Rating (0-10 Low to High Scale)</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire Revised</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory - Interference (0-10 Low to High Scale)</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory, Intensity (0-10 Low to High Scale)</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tampa Scale of Kinesiophobia (17 to 68 Low to High)</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Survey 36; Mental Component Score (T Score Mean of 50)</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Minute Walk Test</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Five Time Sit to Stand Test Rate Per 10 Seconds</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate Vigorous Physical Activity Minutes Per Day</measure>
    <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
    <description>Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>ActiveTENS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo TENS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No TENS (Standard Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS</intervention_name>
    <description>TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit No TENS - Standard Care</description>
    <arm_group_label>ActiveTENS</arm_group_label>
    <arm_group_label>Placebo TENS</arm_group_label>
    <other_name>Empi Select Unit</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be 18 to 70 years of age

          -  Women may participate in the study, with the understanding that within the clinical
             population of fibromyalgia the there is a 7:1 ratio of female to male.

          -  Diagnosis of Fibromyalgia by 1990 ACR criteria (11/18 tender points)

          -  History of cervical or lumbar pain with fibromyalgia (this is expected in all patients
             since axial pain is required for diagnosis)

          -  Current stable treatment regimen for the last 4 weeks and projected stable treatment
             regimen for the next 2 months.

          -  English speaking

        Exclusion Criteria:

          -  Current or history of cardiovascular, pulmonary, neurological, endocrine, or renal
             disease that would preclude the involvement in the study.

          -  TENS use in the last 5 years

          -  Pacemaker

          -  Uncontrolled blood pressure or diabetes

          -  Neuropathic pain condition

          -  Systemic autoimmune disorder (Lupus, PMR, RA, Psoriasis, Psoriatic arthritis)

          -  Spinal fusion - cervical or lumbar

          -  Metal implants in cervical or lumbar region

          -  Severe skin allergy to adhesive

          -  Allergy to nickel

          -  Pain level less than 4

          -  Pregnancy

          -  Epilepsy

          -  Change in or new drug or treatment program within the last month or in the next
             2months, i.e. must have a stable treatment plan

          -  Unstable medical or psychiatric condition which in the opinion of the investigator
             could compromise the subject's welfare or confound the study results
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen A Sluka, PhD, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leslie J. Crofford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37262-2681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://labnodes.vanderbilt.edu/member/profile/id/10689</url>
    <description>Link for Dr. Crofford</description>
  </link>
  <link>
    <url>http://www.medicine.uiowa.edu/pt/pain/</url>
    <description>Dr. Kathleen Sluka</description>
  </link>
  <link>
    <url>http://www.nursing.uiowa.edu/faculty-staff/faculty-directory/rakelb</url>
    <description>Dr. Barb Rakel</description>
  </link>
  <link>
    <url>https://medicine.uiowa.edu/pt/</url>
    <description>Dr. Dana Dailey and Dr. Carol Vance</description>
  </link>
  <reference>
    <citation>Sluka KA, Vance CG, Lisi TL. High-frequency, but not low-frequency, transcutaneous electrical nerve stimulation reduces aspartate and glutamate release in the spinal cord dorsal horn. J Neurochem. 2005 Dec;95(6):1794-801. Epub 2005 Oct 17.</citation>
    <PMID>16236028</PMID>
  </reference>
  <reference>
    <citation>Rakel B, Cooper N, Adams HJ, Messer BR, Frey Law LA, Dannen DR, Miller CA, Polehna AC, Ruggle RC, Vance CG, Walsh DM, Sluka KA. A new transient sham TENS device allows for investigator blinding while delivering a true placebo treatment. J Pain. 2010 Mar;11(3):230-8. doi: 10.1016/j.jpain.2009.07.007. Epub 2009 Nov 27.</citation>
    <PMID>19945354</PMID>
  </reference>
  <reference>
    <citation>Liebano RE, Rakel B, Vance CG, Walsh DM, Sluka KA. An investigation of the development of analgesic tolerance to TENS in humans. Pain. 2011 Feb;152(2):335-42. doi: 10.1016/j.pain.2010.10.040. Epub 2010 Dec 8.</citation>
    <PMID>21144659</PMID>
  </reference>
  <reference>
    <citation>Moran F, Leonard T, Hawthorne S, Hughes CM, McCrum-Gardner E, Johnson MI, Rakel BA, Sluka KA, Walsh DM. Hypoalgesia in response to transcutaneous electrical nerve stimulation (TENS) depends on stimulation intensity. J Pain. 2011 Aug;12(8):929-35. doi: 10.1016/j.jpain.2011.02.352. Epub 2011 Apr 9.</citation>
    <PMID>21481649</PMID>
  </reference>
  <reference>
    <citation>Pantaleão MA, Laurino MF, Gallego NL, Cabral CM, Rakel B, Vance C, Sluka KA, Walsh DM, Liebano RE. Adjusting pulse amplitude during transcutaneous electrical nerve stimulation (TENS) application produces greater hypoalgesia. J Pain. 2011 May;12(5):581-90. doi: 10.1016/j.jpain.2010.11.001. Epub 2011 Feb 1.</citation>
    <PMID>21277840</PMID>
  </reference>
  <reference>
    <citation>DeSantana JM, Walsh DM, Vance C, Rakel BA, Sluka KA. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. Curr Rheumatol Rep. 2008 Dec;10(6):492-9. Review.</citation>
    <PMID>19007541</PMID>
  </reference>
  <reference>
    <citation>Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, Martin SA. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008 Oct;73(1):114-20. doi: 10.1016/j.pec.2008.06.005. Epub 2008 Jul 21.</citation>
    <PMID>18640807</PMID>
  </reference>
  <reference>
    <citation>Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct;36(10):2330-4. doi: 10.3899/jrheum.090368.</citation>
    <PMID>19820222</PMID>
  </reference>
  <reference>
    <citation>Walsh DM, Howe TE, Johnson MI, Sluka KA. Transcutaneous electrical nerve stimulation for acute pain. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006142. doi: 10.1002/14651858.CD006142.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;6:CD006142.</citation>
    <PMID>19370629</PMID>
  </reference>
  <reference>
    <citation>Noehren B, Dailey DL, Rakel BA, Vance CG, Zimmerman MB, Crofford LJ, Sluka KA. Effect of transcutaneous electrical nerve stimulation on pain, function, and quality of life in fibromyalgia: a double-blind randomized clinical trial. Phys Ther. 2015 Jan;95(1):129-40. doi: 10.2522/ptj.20140218. Epub 2014 Sep 11.</citation>
    <PMID>25212518</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2013</study_first_posted>
  <results_first_submitted>June 24, 2019</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2019</results_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Kathleen Sluka</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>TENS</keyword>
  <keyword>Fibromyalgia</keyword>
  <keyword>Accelerometer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>By publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be made available by publication by April 2019 and for one year after closeout of the study and upon request with a proposed study protocol for 5 years.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT01888640/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active TENS</title>
          <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
        </group>
        <group group_id="P2">
          <title>Placebo TENS</title>
          <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
        </group>
        <group group_id="P3">
          <title>No TENS (Standard Care)</title>
          <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="68"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Minimum dose not met</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Given wrong unit (placebo)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded for prior TENS</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Researcher Termination of Participant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active TENS</title>
          <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
        </group>
        <group group_id="B2">
          <title>Placebo TENS</title>
          <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
        </group>
        <group group_id="B3">
          <title>no TENS (Standard Care)</title>
          <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="301"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="14.3"/>
                    <measurement group_id="B2" value="47.2" spread="12.6"/>
                    <measurement group_id="B3" value="48.6" spread="11.8"/>
                    <measurement group_id="B4" value="46.8" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="85"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain with movement six minute walk test</title>
          <units>0 to 10 low to high scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="1.9"/>
                    <measurement group_id="B2" value="6.2" spread="1.9"/>
                    <measurement group_id="B3" value="6.4" spread="1.9"/>
                    <measurement group_id="B4" value="6.4" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain with movement five time sit to stand</title>
          <units>0 to 10 low to high scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="2.4"/>
                    <measurement group_id="B2" value="5.5" spread="2.2"/>
                    <measurement group_id="B3" value="5.6" spread="2.2"/>
                    <measurement group_id="B4" value="5.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain at rest</title>
          <units>0 to 10 low to high scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="1.5"/>
                    <measurement group_id="B2" value="5.9" spread="1.4"/>
                    <measurement group_id="B3" value="6.1" spread="1.6"/>
                    <measurement group_id="B4" value="6.0" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fatigue at rest</title>
          <units>0 to 10 low to high scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.8" spread="2.0"/>
                    <measurement group_id="B2" value="6.1" spread="1.8"/>
                    <measurement group_id="B3" value="6.4" spread="2.0"/>
                    <measurement group_id="B4" value="6.43" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibromyalgia Impact Questionnaire Revised - Pain</title>
          <units>0 to 10 low to high scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="1.8"/>
                    <measurement group_id="B2" value="6.0" spread="1.6"/>
                    <measurement group_id="B3" value="6.15" spread="1.8"/>
                    <measurement group_id="B4" value="6.28" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibromyalgia Impact Questionnaire Revised</title>
          <units>Scoring 0 to 100 low to high scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="16.8"/>
                    <measurement group_id="B2" value="53.7" spread="15.9"/>
                    <measurement group_id="B3" value="55.6" spread="16.0"/>
                    <measurement group_id="B4" value="56.1" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form 36 Physical Component Score</title>
          <description>The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life</description>
          <units>T-score mean of 50</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="6.4"/>
                    <measurement group_id="B2" value="33.3" spread="6.2"/>
                    <measurement group_id="B3" value="32.7" spread="6.6"/>
                    <measurement group_id="B4" value="32.9" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Short Form 36 Mental Health Component Score</title>
          <description>The SF36 Mental Health Component Scale (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life</description>
          <units>T-score mean of 50</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.7" spread="10.0"/>
                    <measurement group_id="B2" value="40.2" spread="10.2"/>
                    <measurement group_id="B3" value="39.5" spread="10.6"/>
                    <measurement group_id="B4" value="39.4" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tampa Scale of Kinesiophobia</title>
          <units>Scoring 17 to 68 low to high</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="7.7"/>
                    <measurement group_id="B2" value="37.1" spread="8.0"/>
                    <measurement group_id="B3" value="37.4" spread="8.3"/>
                    <measurement group_id="B4" value="37" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Six minute walk test (Feet)</title>
          <units>Feet</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1386" spread="323"/>
                    <measurement group_id="B2" value="1358" spread="305"/>
                    <measurement group_id="B3" value="1316" spread="318"/>
                    <measurement group_id="B4" value="1353.3" spread="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Five time sit to stand</title>
          <units>sit-to-stand repetitions/10 seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.1" spread="1.5"/>
                    <measurement group_id="B2" value="4.0" spread="1.4"/>
                    <measurement group_id="B3" value="3.9" spread="1.5"/>
                    <measurement group_id="B4" value="4.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Physical Activity (Moderate-Vigorous)</title>
          <units>Average Minute/Day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.7" lower_limit="7.4" upper_limit="29.0"/>
                    <measurement group_id="B2" value="16.5" lower_limit="6.3" upper_limit="29.1"/>
                    <measurement group_id="B3" value="15.0" lower_limit="7.3" upper_limit="36.0"/>
                    <measurement group_id="B4" value="16.4" lower_limit="6.3" upper_limit="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test</title>
        <description>Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Rating With Movement (0-10 Low to High Scale) During Six Minute Walk Test</title>
          <description>Numeric rating scale of 0-10 (low to high scale) for pain with movement during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-2.3" upper_limit="-1.2"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-1.4" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-0.5" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-2.8" upper_limit="-1.3"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-2.7" upper_limit="-1.2"/>
                    <measurement group_id="O3" value="-1.9" lower_limit="-2.6" upper_limit="-1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2-Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>To account for multiple tests involving pairwise treatment group comparisons, p-values were adjusted using Bonferroni’s method</p_value_desc>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test</title>
        <description>Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Rating With Movement (0-10 Low to High Scale) During Five Time Sit to Stand Test</title>
          <description>Numeric rating scale of 0-10 for pain with movement with five time sit to stand test. Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" lower_limit="-2.30" upper_limit="-1.0"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.0" upper_limit="0.3"/>
                    <measurement group_id="O3" value="0.2" lower_limit="-0.4" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-2.6" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-1.4" lower_limit="-2.2" upper_limit="-0.7"/>
                    <measurement group_id="O3" value="-1.3" lower_limit="-2.1" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Pain (0-10 Low to High Scale)</title>
        <description>Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Pain (0-10 Low to High Scale)</title>
          <description>Numeric rating scale of 0-10 for resting pain; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-2.5" upper_limit="-1.4"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.3" upper_limit="-0.1"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1.1" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" lower_limit="-2.9" upper_limit="-1.6"/>
                    <measurement group_id="O2" value="-1.9" lower_limit="-2.6" upper_limit="-1.2"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-2.8" upper_limit="-1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test</title>
        <description>Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Rating (0-10 Low to High Scale) During Six Minute Walk Test</title>
          <description>Fatigue measured with 0-10 numeric rating scale during six minute walk test; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-2.2" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.9" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.4" lower_limit="-0.3" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-2.0" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.7" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-1.7" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand</title>
        <description>Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Rating (0-10 Low to High Scale) During Five Time Sit to Stand</title>
          <description>Fatigue measured by 0-10 numeric rating scale after five time sit to stand; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" lower_limit="-1.9" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.8" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.1" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.9" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-1.6" upper_limit="-0.1"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-1.4" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting Fatigue Rating (0-10 Low to High Scale)</title>
        <description>Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <population>Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)</population>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Resting Fatigue Rating (0-10 Low to High Scale)</title>
          <description>Fatigue measured at rest with a 0-10 numeric rating scale; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <population>Baseline, Visit 2 to Visit 3 (4 weeks, randomized to 3 groups) and Visit 4 (4 weeks, all groups home TENS)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" lower_limit="-2.6" upper_limit="-1.2"/>
                    <measurement group_id="O2" value="-0.8" lower_limit="-1.5" upper_limit="-0.04"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-1.0" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" lower_limit="-2.9" upper_limit="-1.4"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-2.4" upper_limit="-0.8"/>
                    <measurement group_id="O3" value="-1.8" lower_limit="-2.6" upper_limit="-1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibromyalgia Impact Questionnaire Revised</title>
        <description>Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibromyalgia Impact Questionnaire Revised</title>
          <description>Disease Impact self report Questionnaire, Scoring 0-100; higher score indicates greater disease impact; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" lower_limit="-12.9" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-6.5" upper_limit="0.3"/>
                    <measurement group_id="O3" value="-1.39" lower_limit="-4.4" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" lower_limit="-13.8" upper_limit="5.4"/>
                    <measurement group_id="O2" value="-11.1" lower_limit="-15.2" upper_limit="7.0"/>
                    <measurement group_id="O3" value="-10.7" lower_limit="-14.8" upper_limit="-6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.074</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.4</ci_lower_limit>
            <ci_upper_limit>-1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)</title>
        <description>numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Fibromyalgia Impact Questionnaire Revised - Pain Rating (0-10 Low to High Scale)</title>
          <description>numeric rating scale 0 to 10 from the Fibromyalgia Impact Questionnaire Revised: Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.8" upper_limit="-0.7"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-0.9" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.6" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-2.0" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-1.7" upper_limit="-0.6"/>
                    <measurement group_id="O3" value="-1.4" lower_limit="-1.9" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory - Interference (0-10 Low to High Scale)</title>
        <description>Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory - Interference (0-10 Low to High Scale)</title>
          <description>Brief Pain Inventory - Interference; Score 0-10 with higher score indicating greater interference; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-1.4" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.7" upper_limit="0.2"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.7" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.6" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.4" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-1.7" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.043</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory, Intensity (0-10 Low to High Scale)</title>
        <description>Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory, Intensity (0-10 Low to High Scale)</title>
          <description>Brief Pain Inventory - Interference, Scale of 0-10 with higher score indicating greater intensity; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-1.1" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-0.6" upper_limit="0.1"/>
                    <measurement group_id="O3" value="0.15" lower_limit="-0.2" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.4" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.3" upper_limit="-0.5"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-1.2" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tampa Scale of Kinesiophobia (17 to 68 Low to High)</title>
        <description>Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Tampa Scale of Kinesiophobia (17 to 68 Low to High)</title>
          <description>Self report questionnaire with higher scores indicating greater kinesiophobia, score 17-68; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-2.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-1.7" upper_limit="1.0"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-1.4" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.6" upper_limit="1.1"/>
                    <measurement group_id="O2" value="-2.3" lower_limit="-3.7" upper_limit="-0.9"/>
                    <measurement group_id="O3" value="-3.3" lower_limit="-4.6" upper_limit="-2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Survey 36; Mental Component Score (T Score Mean of 50)</title>
        <description>Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Survey 36; Mental Component Score (T Score Mean of 50)</title>
          <description>Multidimensional Self Report Questionnaire, T-score; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
The SF36 Mental Health Component Score (MCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.2" upper_limit="4.4"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-0.9" upper_limit="3.4"/>
                    <measurement group_id="O3" value="-0.04" lower_limit="-2.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="-0.2" upper_limit="4.4"/>
                    <measurement group_id="O2" value="3.6" lower_limit="1.3" upper_limit="6.0"/>
                    <measurement group_id="O3" value="2.8" lower_limit="0.6" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health</title>
        <description>Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Short Form Survey 36 Physical Component Score (T-score Mean of 50) Higher Scores Indicating Better Health</title>
          <description>Multidimensional self report scale, T score change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups
The SF36 Physical Functioning Component Score (PCS) quality of life measure. A T-Score of 50 represents the mean, with a standard deviation of 10, values less than 50 indicate a less than average score while values greater than 50 indicate greater than average scores&quot; . Higher T-scores reflect better quality of life and lower T-score reflect lesser quality of life .</description>
          <units>T-Score</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.0" upper_limit="3.7"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-0.2" upper_limit="2.5"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.1" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1.6" upper_limit="4.8"/>
                    <measurement group_id="O3" value="4.4" lower_limit="2.9" upper_limit="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Minute Walk Test</title>
        <description>6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Six Minute Walk Test</title>
          <description>6MWT - Feet walked as fast as comfortable in six minute; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>Feet</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-55" upper_limit="54"/>
                    <measurement group_id="O2" value="-20" lower_limit="-75" upper_limit="36"/>
                    <measurement group_id="O3" value="-42.1" lower_limit="-95" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="-42" upper_limit="71"/>
                    <measurement group_id="O2" value="16" lower_limit="-41" upper_limit="74"/>
                    <measurement group_id="O3" value="-2" lower_limit="-57" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58</ci_lower_limit>
            <ci_upper_limit>96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34</ci_lower_limit>
            <ci_upper_limit>117</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Five Time Sit to Stand Test Rate Per 10 Seconds</title>
        <description>Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Five Time Sit to Stand Test Rate Per 10 Seconds</title>
          <description>Time for sit to stand for 5 repetitions converted to a rate of number of sit to stand per 10 seconds; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>sit-to-stand repetitions/10 seconds</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.3" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.0" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.3" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.4" upper_limit="1.3"/>
                    <measurement group_id="O3" value="0.6" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.96</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Linear mixed models for repeated measure</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Moderate Vigorous Physical Activity Minutes Per Day</title>
        <description>Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
        <time_frame>Time Frame: Baseline (Visit 2), 4 weeks (Visit 3, randomized to 3 groups), and 8 weeks (Visit 4, all groups home TENS)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active TENS</title>
            <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O2">
            <title>Placebo TENS</title>
            <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 2-125 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
          </group>
          <group group_id="O3">
            <title>No TENS (Standard Care)</title>
            <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Moderate Vigorous Physical Activity Minutes Per Day</title>
          <description>Accelerometry data classification of physical activity in minutes per day, percent change; Intention to treat analysis corrected for site (Iowa and Vanderbilt) differences. Mean change (from baseline, Visit 2) at Visit 3 (after 4 weeks of home TENS use, or placebo TENS, or no TENS) and at Visit 4 (after 4 weeks of home TENS all groups) with 95% adjusted confidence intervals. Change scores are presented for the randomized phase between Visit-2 and Visit-3, and for the difference from baseline at Visit 4 when all subjects received active-TENS. p-values represent post hoc comparisons between groups</description>
          <units>Minutes per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.4" lower_limit="-27.8" upper_limit="13.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="-18.6" upper_limit="29.1"/>
                    <measurement group_id="O3" value="-14.1" lower_limit="-29.5" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at 8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.8" lower_limit="-27.2" upper_limit="19.3"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-22.3" upper_limit="27.9"/>
                    <measurement group_id="O3" value="-17.0" lower_limit="-33.9" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Visit 2 to Visit 3</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.99</p_value>
            <method>Linear mixed models for repeated measure</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Visit 1 to Visit 4, 9 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active TENS</title>
          <description>Active TENS for 4 weeks of the study and will add an additional 4 weeks of active TENS for the last 4 weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
        </group>
        <group group_id="E2">
          <title>Placebo TENS</title>
          <description>This group will receive placebo TENS for the first 4 weeks of the study and then active TENS for the last four weeks of the study.
TENS: TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS</description>
        </group>
        <group group_id="E3">
          <title>No TENS (Standard Care)</title>
          <description>Subjects will not receive TENS intervention during the first 4 weeks of the trial but will complete all testing procedures as the other two arms. This group will receive active TENS during the last 4 weeks of the study.</description>
        </group>
        <group group_id="E4">
          <title>Pre-Randomization</title>
          <description>Participants who attended visit 1 or 2 prior to randomization to intervention</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <description>Subject with chest pain between visits with emergency department visit and hospitalization; non-study related, recovered with treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration and gastrointestinal pain</sub_title>
                <description>Participant admitted to hospital for complaint of dehydration</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>Hospitalization for depression</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain with TENS; At home, unspecified</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Headache or Migraine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Dental Procedures</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain with testing</sub_title>
                <description>Increase in pain with testing at clinic visit</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory</sub_title>
                <description>Report of upper respiratory infection or difficulty during the study</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Irritation from actigraph band</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
              <event>
                <sub_title>Skin Irritation with Electrodes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="352"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kathleen A. Sluka</name_or_title>
      <organization>University of Iowa</organization>
      <phone>319-335-9791</phone>
      <email>kathleen-sluka@uiowa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

